TAIMA TB 3HP STUDY: ACCEPTABILITY AND COMPLETION RATES OF A NEW 12 DOSE TREATMENT (3 MONTH) COMPARED TO THE STANDARD TREATMENT FOR LATENT TB INFECTION TREATMENT

Registry ID

3HP-IQ-OT-01

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

OTTAWA HOSPITAL RESEARCH INSTITUTE

Start date

2016-05-30

Completion date

2020-01-03

Last update

2016-01-21

Conditions

• LATENT TUBERCULOSIS (TB) INFECTION

Related clinical trials

• STUDY 38 - PHASE 2C CLINICAL TRIAL OF NOVEL, SHORT-COURSE REGIMENS FOR THE TREATMENT OF PULMONARY TUBERCULOSIS: CRUSH-TB (COMBINATION REGIMENS FOR SHORTENING TB TREATMENT)
• SSTARLET: SHORTER AND SAFER TREATMENT REGIMENS FOR LATENT TB
• SIX WEEKS OF DAILY RIFAPENTINE VS. A COMPARATOR ARM OF 12-16 WEEK RIFAMYCIN-BASED TREATMENT OF LATENT M. TUBERCULOSIS INFECTION: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFECTIVENESS
• 2R2: HIGHER DOSE RIFAMPIN FOR 2 MONTHS VS STANDARD DOSE RIFAMPIN FOR LATENT TB:A 3-ARM RANDOMIZED TRIAL

View on source registry